Abstract: The invention discloses a composition of nanoparticles composed of positively charged chitosan, one negatively charged substrate, and optionally a zero-charge compound or at least one tumor necrosis factor inhibitor for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Abstract: The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one DNA, RNA or bioactive agent characterized with a positive surface charge and their enhanced efficiency for gene delivery and bioactive agent delivery.

Abstract: The invention discloses the nanoparticles composed of chitosan, poly-?-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.

Abstract: The invention discloses a pharmaceutical composition of multifunctional core-shell nanoparticles, each nanoparticle comprising: a core portion comprised of hydrophobic poly(D,L-lactic-co-glycolic acid) (PLGA) and a detection-enhancing substance, and a shell portion comprised of positively charged chitosan adapted to cause no aggregation of nanoparticles due to electrostatic repulsion between the positively charged nanoparticles. In one embodiment, the detection-enhancing substance includes SPIO, a quantum dot, a fluorescent quantum dot, a bubble, an air bubble, and the like.

Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Abstract: Devices and methods for treating ocular disorders are disclosed. One ocular implant, has a substantially straight, rigid, elongate body. The body has a self-trephinating distal portion that narrows toward a distal end, and at least one inlet that communicates with at least one inner lumen that communicates with a plurality of outlets. The lumen has a sufficient length to extend from an anterior chamber of an eye to a physiologic outflow pathway. An anchor member extends from the implant.

Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for drug delivery.

Abstract: Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber. The implant is implanted into eye tissue adjacent the anterior chamber. A therapeutic agent is eluted from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent a choroid of the eye. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension. The therapeutic agent can be contained within the implant or coated on the implant.

Abstract: The invention relates generally to medical devices and methods for the treatment of ocular disorders. One method provides an implant having an inlet portion with a first anchor and an outlet portion with a second anchor. The implant is implanted in tissue of an eye such the implant conducts fluid from an anterior chamber of the eye to a physiological outflow pathway of the eye. The implanting involves positioning the first anchor adjacent eye tissue, positioning the second anchor within the physiological outflow pathway, and deploying the second anchor such that the second anchor secures the implant within the physiological outflow pathway and a distal end of the second anchor is positioned further into the physiological outflow pathway than an outlet of the outlet portion.

Abstract: The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Abstract: A catheter system for repairing an annular organ structure of a patient, comprising: intimately contacting the annular organ structure by a tissue-contactor member having energy-delivering elements; and delivering tissue-shrinkable energy at the annular organ structure through the elements, wherein the tissue-shrinkable energy is applied at a distance wirelessly from the elements sufficient to shrink and tighten the organ structure. Tissue-shrinkable energy is infrared energy, ultrasound energy, focused ultrasound energy, ultrasound energy, radiofrequency energy, microwave energy, electromagnetic energy, laser energy, or a combination thereof.

Abstract: The invention discloses a pharmaceutical composition of liposome nanoparticles for lodging in a target tissue cell in situ of an animal subject, the nanoparticles comprising at least one thermal triggered phase-transition compound as a targeting drug delivery system for physical cancer therapy.

Abstract: The invention discloses a pharmaceutical composition of liposome nanoparticles for lodging in a target tissue cell in situ of an animal subject, the nanoparticles comprising at least one thermal triggered phase-transition compound as a targeting drug delivery system for physical cancer therapy.

Abstract: A gastric space filler device for treating obesity in a patient by reducing the stomach features at least one inflatable space filler with drug delivery and stimulation features and includes therapeutic devices and anchoring apparatus enabling tracking, is and optimized management of inter-balloon connecting sections, drug reservoirs and pumping systems along with related improvements.

Abstract: A medical device and methods to relieve joint pain and adapted for knee joint repair, replacement and augmentation. The invention discloses joint lubricant, particularly hyaluronate compositions and methods for treatment of osteoarthritis.

Abstract: The invention discloses a composition of chitosan-shelled nanoparticles and methods of manufacturing. The chitosan-shelled nanoparticles are characterized with a positive surface charge and enhanced epithelial permeability for oral drug delivery.

Abstract: The invention discloses a trabecular stent and methods for treating glaucoma. The stent may incorporate an intraocular pressure sensor comprising a compressible element that is implanted inside an anterior chamber of an eye, wherein at least one external dimension of the element correlates with intraocular pressure. In some embodiments, the sensor may be coupled to the stent. Also disclosed are methods of delivery of the stent and the sensor to the eye.

Abstract: The invention discloses particulate complexes composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein equal moles of the positively charged chitosan and the negatively charged poly-glutamic acid substrate form an electrostatic network enabling improved loading the bioactive agent.